Down-regulation of vascular endothelial growth factor expression by anti-her2/neu single chain antibodies

Medical Oncology

Volumn 29, Issue 1, 2012, Pages 378-383

  Nejatollahi, Foroogh ^a   Asgharpour, Mahdi ^a,b   Jaberipour, Mansooreh ^c  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Angiogenesis; Breast cancer; HER2 neu; Single chain antibody; VEGF

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; VASCULOTROPIN;

ARTICLE; BREAST CANCER; DNA FINGERPRINTING; DOWN REGULATION; GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; VASCULOTROPIN GENE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; GENE EXPRESSION; HUMANS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SINGLE-CHAIN ANTIBODIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84864055012     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9796-5     Document Type: Article

References (43)

1. Hung MC, Lau YK. Basic science of HER-2/neu: a review. Semin Oncol. (1999);26(4 Suppl 12):51-9.
2. Jemal A, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2): 71-96. (Pubitemid 351521864)
3. Natali PG, et al. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer. 1990;45(3):457-61. (Pubitemid 20087192)
4. Brennan PJ, et al. HER2/Neu: mechanisms of dimerization/oli-gomerization. Oncogene. (2002);21(2):328.
5. Zaczek A, Brandt B, Bielawski KP. The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol. 2005;20(3):1005-15. (Pubitemid 40932618)
6. Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene. 2000;19(53):6102-14. (Pubitemid 32059460)
7. Zhou BP, Hung MC. Dysregulation of cellular signaling by HER2/neu in breast cancer. Semin Oncol. (2003);30(5 Suppl 16): 38-48. (Pubitemid 37433395)
8. Petit AM, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997;151(6):1523-30. (Pubitemid 27527914)
9. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol. 2001;280(6):C1358-66. (Pubitemid 32553190)
10. Gupta K, et al. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res. 1999;247(2):495-504. (Pubitemid 29394787)
11. Pidgeon GP, et al. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer. 2001;85(2):273-8. (Pubitemid 32695751)
12. Tran J, et al. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun. 1999;264(3):781-8.
13. Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol. 2001;280(6):C1375-86. (Pubitemid 32553192)
14. Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature. 2005;437(7058): 497-504. (Pubitemid 41613541)
15. Shepard HM, Slamon DJ, Pirot Z, Maneval DC. Herceptin. Handb Exp Pharmacol. 2008;181:183-219.
16. FDA expands us of herceptin for early-stage breast cancer. Mayo Clin Womens Healthsource. 2007;11(6):3.
17. Burris H 3rd, et al. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol. 2004;22(9):1621-9.
18. Vogel CL, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719-26. (Pubitemid 34111379)
19. Nielsen DL, Andersson M, Kamby C. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev. 2009;35(2):121-36.
20. Metzger Filho O, Saini KS, Azim HA, Jr., Awada A (2010)Pre-vention and management of major side effects of targeted agents in breast cancer. Crit Rev Oncol Hematol.
21. Du XL, Xia R, Burau K, Liu CC (2010)Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998-2005. Med Oncol.
22. Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol. 2009;48(7): 964-70.
23. Nuttall SD, Irving RA, Hudson PJ. Immunoglobulin VH domains and beyond: design and selection of single-domain binding and targeting reagents. Curr Pharm Biotechnol. 2000;1(3):253-63.
24. Batra SK, et al. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol. 2002;13(6): 603-8. (Pubitemid 35448063)
25. Curigliano G, et al. Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis. 2010;53(2): 94-104.
26. Nejatollahi F, Hodgetts SJ, Vallely PJ, Burnie JP. Neutralising human recombinant antibodies to human cytomegalovirus gly-coproteins gB and gH. FEMS Immunol Med Microbiol. 2002; 34(3):237-44. (Pubitemid 35335525)
27. Nahta R, Esteva FJ. In vitro effects of trastuzumab and vinorel-bine in trastuzumab-resistant breast cancer cells. Cancer Che-mother Pharmacol. 2004;53:186-90. (Pubitemid 38186999)
28. Kern FG, Lippman ME. The role of angiogenic growth factors in breast cancer progression. Cancer Metastasis Rev. 1996;15(2): 213-9. (Pubitemid 26236119)
29. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angio-genesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):1-8.
30. Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? Cell. 1996;87(7):1153-5. (Pubitemid 27010098)
31. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem. 1996;271(2):603-6. (Pubitemid 26034900)
32. Foekens JA, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res. 2001;61(14):5407-14. (Pubitemid 32694919)
33. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist. (2000);5 Suppl 1: 37-44. (Pubitemid 30225456)
34. Konecny GE, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res. 2004;10(5): 1706-16. (Pubitemid 38435562)
35. Schoppmann SF, et al. HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer. Ann Oncol. 2010;21(5): 955-60.
36. Linderholm B, et al. Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment. Eur J Cancer. 2004;40(1):33-42. (Pubitemid 37542315)
37. Loureiro RM, et al. ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter. Biochem Biophys Res Commun. 2005;326(2):455-65. (Pubitemid 39593568)
38. Pegram MD, Reese DM. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Semin Oncol. (2002);29(3 Suppl 11):29-37. (Pubitemid 34816063)
39. Yen L, et al. Differential regulation of tumor angiogenesis by distinct ErbB homo\and heterodimers. Mol Biol Cell. 2002; 13(11):4029-44. (Pubitemid 35398568)
40. Wen XF, et al. HER2 signaling modulates the equilibrium between pro\and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene. 2006;25(52):6986-96.
41. Scott LJ. Bevacizumab: in first-line treatment of metastatic breast cancer. Drugs. 2007;67(12):1793-9. (Pubitemid 47263182)
42. Yen L, et al. Heregulin selectively upregulates vascular endo-thelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene. 2000;19(31):3460-9. (Pubitemid 30487443)
43. Montgomery RB, et al. Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res. 2005;65(2):650-6.